Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 6575 · CommonGround for Affordable Health Care Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 36B Refundable credit for coverage under a qualified health plan

+12 −43 of 5 shown
More for 26 U.S.C. § 36B
Read § 36BOnly this section
5 changes the bill asks for here, 3 carried out
  1. Carried out:

    by redesignating subclauses (I) and (II) as items (aa) and (bb), respectively, and adjusting the margins accordingly,

  2. Not carried out:

    by striking Temporary percentages for 2021 through 2025.—In the case of and inserting (I) Before 2026.— In the case of Temporary percentages for certain years.—, and

    § 36B(b)(3)(A)(iii) already has provisions of its own, so its opening words can't simply become the first of them.

    Technical detail/us/usc/t26/s36B/b/3/A/iii has provisions already, so its words can't become the first
  3. Carried out:

    by adding at the end the following:(II) 2026.— In the case of a taxable year beginning after December 31, 2025, and before January 1, 2027— (aa) clause (ii) shall not apply for purposes of adjusting premium percentages under this subparagraph, and (bb) the following table shall be applied in lieu of the table contained in clause (i):.

  4. Not carried out:

    by striking Temporary rule for 2021 through 2025.—In the case of and inserting (i) Before 2026.— In the case of Temporary rule for certain years.—, and

    The bill turns “Temporary rule for 2021 through 2025.—In the case of” into a provision of its own, but in § 36B(c)(1)(E) the text doesn't begin with those words. The law may have changed since the bill was drafted.

    Technical detail“Temporary rule for 2021 through 2025.—In the case of” does not open the text of /us/usc/t26/s36B/c/1/E
  5. Carried out:

    by adding at the end the following:(ii) 2026.— In the case of a taxable year beginning after December 31, 2025, and before January 1, 2027, subparagraph (A) shall be applied by substituting “but does not exceed 1000 percent” for “but does not exceed 400 percent”..

§ 36B(b)(3)Other terms and rules relating to premium assistance amounts(A)–(B)

Start of § 36B to (b)(3)(A)(ii)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(A)(ii)(III)(III) Failsafe(III) Failsafe
Subclause (II) shall apply for any calendar year only if the aggregate amount of premium tax credits under this section and cost-sharing reductions under section 1402 of the Patient Protection and Affordable Care Act for the preceding calendar year exceeds an amount equal to 0.504 percent of the gross domestic product for the preceding calendar year.Subclause (II) shall apply for any calendar year only if the aggregate amount of premium tax credits under this section and cost-sharing reductions under section 1402 of the Patient Protection and Affordable Care Act for the preceding calendar year exceeds an amount equal to 0.504 percent of the gross domestic product for the preceding calendar year.
(A)(iii)(iii) Temporary percentages for 2021 through 2025(iii) Temporary percentages for 2021 through 2025
In the case of a taxable year beginning after December 31, 2020, and before January 1, 2026—In the case of a taxable year beginning after December 31, 2020, and before January 1, 2026—
(A)(iii)(aa)[struck: (I)] [inserted: (aa)]
clause (ii) shall not apply for purposes of adjusting premium percentages under this subparagraph, andclause (ii) shall not apply for purposes of adjusting premium percentages under this subparagraph, and
(A)(iii)(bb)[struck: (II)] [inserted: (bb)]
the following table shall be applied in lieu of the table contained in clause (i): In the case of household income (expressed as a percent of poverty line) within the following income tier: The initial premium percentage is— The final premium percentage is— Up to 150.0 percent 0.0 0.0 150.0 percent up to 200.0 percent 0.0 2.0 200.0 percent up to 250.0 percent 2.0 4.0 250.0 percent up to 300.0 percent 4.0 6.0 300.0 percent up to 400.0 percent 6.0 8.5 400.0 percent and higher 8.5 8.5the following table shall be applied in lieu of the table contained in clause (i): In the case of household income (expressed as a percent of poverty line) within the following income tier: The initial premium percentage is— The final premium percentage is— Up to 150.0 percent 0.0 0.0 150.0 percent up to 200.0 percent 0.0 2.0 200.0 percent up to 250.0 percent 2.0 4.0 250.0 percent up to 300.0 percent 4.0 6.0 300.0 percent up to 400.0 percent 6.0 8.5 400.0 percent and higher 8.5 8.5
(A)(iii)(II)(II) [inserted: 2026.—]
[inserted: In the case of a taxable year beginning after December 31, 2025, and before January 1, 2027—]
(A)(iii)(II)(aa)(aa) [inserted: ]
[inserted: clause (ii) shall not apply for purposes of adjusting premium percentages under this subparagraph, and]
(A)(iii)(II)(bb)(bb) [inserted: ]
[inserted: the following table shall be applied in lieu of the table contained in clause (i):]
(B)(B) Applicable second lowest cost silver plan(B) Applicable second lowest cost silver plan
The applicable second lowest cost silver plan with respect to any applicable taxpayer is the second lowest cost silver plan of the individual market in the rating area in which the taxpayer resides which—The applicable second lowest cost silver plan with respect to any applicable taxpayer is the second lowest cost silver plan of the individual market in the rating area in which the taxpayer resides which—
(B)(i)(i) (i)
is offered through the same Exchange through which the qualified health plans taken into account under paragraph (2)(A) were offered, andis offered through the same Exchange through which the qualified health plans taken into account under paragraph (2)(A) were offered, and

§ 36B(c)Definition and rules relating to applicable taxpayers, coverage months, and qualified health plan(1)–(2)

(b)(3)(B)(ii)–(c)(1)(C) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(D)(D) Denial of credit to dependents(D) Denial of credit to dependents
No credit shall be allowed under this section to any individual with respect to whom a deduction under section 151 is allowable to another taxpayer for a taxable year beginning in the calendar year in which such individual’s taxable year begins.No credit shall be allowed under this section to any individual with respect to whom a deduction under section 151 is allowable to another taxpayer for a taxable year beginning in the calendar year in which such individual’s taxable year begins.
(1)(E)(E) Temporary rule for 2021 through 2025(E) Temporary rule for 2021 through 2025
In the case of a taxable year beginning after December 31, 2020, and before January 1, 2026, subparagraph (A) shall be applied without regard to “but does not exceed 400 percent”.In the case of a taxable year beginning after December 31, 2020, and before January 1, 2026, subparagraph (A) shall be applied without regard to “but does not exceed 400 percent”.
(1)(E)(ii)(ii) [inserted: 2026.—]
[inserted: In the case of a taxable year beginning after December 31, 2025, and before January 1, 2027, subparagraph (A) shall be applied by substituting “but does not exceed 1000 percent” for “but does not exceed 400 percent”.]
(2)(2) Coverage month(2) Coverage month
For purposes of this subsection—For purposes of this subsection—
(2)(A)(A) In general(A) In general
The term “coverage month” means, with respect to an applicable taxpayer, any month if—The term “coverage month” means, with respect to an applicable taxpayer, any month if—

Rest of § 36B unchanged

42 U.S.C. § 1395w–27 Contracts with Medicare+Choice organizations

+2 −0Shown
More for 42 U.S.C. § 1395w–27
Read § 1395w–27Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–27(f)(3)) is amended by adding at the end the following new subparagraph:(F) Requirements relating to pharmacy benefit managers.— For plan years beginning on or after January 1, 2029, section 1860D–12(h)..

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 1395w–27(f)–(g)

Start of § 1395w–27 to (f)(3)(E) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(f)(3)(F)(F) Accountability of pharmacy benefit managers for violations of reasonable and relevant contract terms(F) Accountability of pharmacy benefit managers for violations of reasonable and relevant contract terms
For plan years beginning on or after January 1, 2029, section 1395w–112(b)(9) of this title.For plan years beginning on or after January 1, 2029, section 1395w–112(b)(9) of this title.
(f)(3)(G)(G) Requirements relating to pharmacy benefit managers(G) Requirements relating to pharmacy benefit managers
For plan years beginning on or after January 1, 2028, section 1395w–112(h) of this title.For plan years beginning on or after January 1, 2028, section 1395w–112(h) of this title.
(f)(3)(F)(F) [inserted: Requirements relating to pharmacy benefit managers.—]
[inserted: For plan years beginning on or after January 1, 2029, section 1860D–12(h).]
(g)(g) Intermediate sanctions(g) Intermediate sanctions
(g)(1)(1) In general(1) In general
If the Secretary determines that a Medicare+Choice organization with a contract under this section—If the Secretary determines that a Medicare+Choice organization with a contract under this section—

Rest of § 1395w–27 unchanged

42 U.S.C. § 1395w–112 Requirements for and contracts with prescription drug plan (PDP) sponsors

+220 −0Shown
More for 42 U.S.C. § 1395w–112
Read § 1395w–112Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–12 of the Social Security Act (42 U.S.C. 1395w–112) is amended by adding at the end the following new subsection:(h) Requirements relating to pharmacy benefit managers.— For plan years beginning on or after January 1, 2029: (1) Agreements with pharmacy benefit managers.— Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such …

    The section already has a provision under this letter or number, so it would have two.

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 1395w–112(h)–(h)

Start of § 1395w–112 to (h)(7)(B)(iii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(h)(7)(B)(iv)(iv) (iv)
any other amounts or methodologies prohibited by the Secretary.any other amounts or methodologies prohibited by the Secretary.
(h)(7)(C)(C) Pharmacy benefit manager(C) Pharmacy benefit manager
The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a PDP sponsor or prescription drug plan, or manages the prescription drug benefits provided by such sponsor or plan, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered part D drugs, or the provision of related services. Such term includes any person or entity that carries out one or more of the activities described in the preceding sentence, irrespective of whether such person or entity calls itself a “pharmacy benefit manager”.The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a PDP sponsor or prescription drug plan, or manages the prescription drug benefits provided by such sponsor or plan, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered part D drugs, or the provision of related services. Such term includes any person or entity that carries out one or more of the activities described in the preceding sentence, irrespective of whether such person or entity calls itself a “pharmacy benefit manager”.
(h)(h) [inserted: Requirements relating to pharmacy benefit managers.—]
[inserted: For plan years beginning on or after January 1, 2029:]
(h)(1)(1) [inserted: Agreements with pharmacy benefit managers.—]
[inserted: Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such sponsor shall provide that any pharmacy benefit manager acting on behalf of such sponsor has a written agreement with the PDP sponsor under which the pharmacy benefit manager, and any affiliates of such pharmacy benefit manager, as applicable, agree to meet the following requirements:]
(h)(1)(A)(A) [inserted: No income other than bona fide service fees.—]
(h)(1)(A)(i)(i) [inserted: In general.—]
[inserted: The pharmacy benefit manager and any affiliate of such pharmacy benefit manager shall not derive any remuneration with respect to any services provided on behalf of any entity or individual, in connection with the utilization of covered part D drugs, from any such entity or individual other than bona fide service fees, subject to clauses (ii) and (iii).]
(h)(1)(A)(ii)(ii) [inserted: Incentive payments.—]
[inserted: For the purposes of this subsection, an incentive payment (as determined by the Secretary) paid by a PDP sponsor to a pharmacy benefit manager that is performing services on behalf of such sponsor shall be deemed a “bona fide service fee” (even if such payment does not otherwise meet the definition of such term under paragraph (7)(B)) if such payment is a flat dollar amount, is consistent with fair market value (as specified by the Secretary), is related to services actually performed by the pharmacy benefit manager or affiliate of such pharmacy benefit manager, on behalf of the PDP sponsor making such payment, in connection with the utilization of covered part D drugs, and meets additional requirements, if any, as determined appropriate by the Secretary.]
(h)(1)(A)(iii)(iii) [inserted: Clarification on rebates and discounts used to lower costs for covered part d drugs.—]
[inserted: Rebates, discounts, and other price concessions received by a pharmacy benefit manager or an affiliate of a pharmacy benefit manager from manufacturers, even if such price concessions are calculated as a percentage of a drug’s price, shall not be considered a violation of the requirements of clause (i) if they are fully passed through to a PDP sponsor and are compliant with all regulatory and subregulatory requirements related to direct and indirect remuneration for manufacturer rebates under this part, including in cases where a PDP sponsor is acting as a pharmacy benefit manager on behalf of a prescription drug plan offered by such PDP sponsor.]
(h)(1)(A)(iv)(iv) [inserted: Evaluation of remuneration arrangements.—]
[inserted: Components of subsets of remuneration arrangements (such as fees or other forms of compensation paid to or retained by the pharmacy benefit manager or affiliate of such pharmacy benefit manager), as determined appropriate by the Secretary, between pharmacy benefit managers or affiliates of such pharmacy benefit managers, as applicable, and other entities involved in the dispensing or utilization of covered part D drugs (including PDP sponsors, manufacturers, pharmacies, and other entities as determined appropriate by the Secretary) shall be subject to review by the Secretary, in consultation with the Office of the Inspector General of the Department of Health and Human Services, as determined appropriate by the Secretary. The Secretary, in consultation with the Office of the Inspector General, shall review whether remuneration under such arrangements is consistent with fair market value (as specified by the Secretary) through reviews and assessments of such remuneration, as determined appropriate.]
(h)(1)(A)(v)(v) [inserted: Disgorgement.—]
[inserted: The pharmacy benefit manager shall disgorge any remuneration paid to such pharmacy benefit manager or an affiliate of such pharmacy benefit manager in violation of this subparagraph to the PDP sponsor.]
(h)(1)(A)(vi)(vi) [inserted: Additional requirements.—]
[inserted: The pharmacy benefit manager shall—]
(h)(1)(A)(vi)(I)(I) [inserted: ]
[inserted: enter into a written agreement with any affiliate of such pharmacy benefit manager, under which the affiliate shall identify and disgorge any remuneration described in clause (v) to the pharmacy benefit manager; and]
(h)(1)(A)(vi)(II)(II) [inserted: ]
[inserted: attest, subject to any requirements determined appropriate by the Secretary, that the pharmacy benefit manager has entered into a written agreement described in subclause (I) with any relevant affiliate of the pharmacy benefit manager.]
(h)(1)(B)(B) [inserted: Transparency regarding guarantees and cost performance evaluations.—]
[inserted: The pharmacy benefit manager shall—]
(h)(1)(B)(i)(i) [inserted: ]
[inserted: define, interpret, and apply, in a fully transparent and consistent manner for purposes of calculating or otherwise evaluating pharmacy benefit manager performance against pricing guarantees or similar cost performance measurements related to rebates, discounts, price concessions, or net costs, terms such as—]
(h)(1)(B)(i)(I)(I) [inserted: ]
[inserted: “generic drug”, in a manner consistent with the definition of the term under section 423.4 of title 42, Code of Federal Regulations, or a successor regulation;]
(h)(1)(B)(i)(II)(II) [inserted: ]
[inserted: “brand name drug”, in a manner consistent with the definition of the term under section 423.4 of title 42, Code of Federal Regulations, or a successor regulation;]
(h)(1)(B)(i)(III)(III) [inserted: ]
[inserted: “specialty drug”;]
(h)(1)(B)(i)(IV)(IV) [inserted: ]
[inserted: “rebate”; and]
(h)(1)(B)(i)(V)(V) [inserted: ]
[inserted: “discount”;]
(h)(1)(B)(ii)(ii) [inserted: ]
[inserted: identify any drugs, claims, or price concessions excluded from any pricing guarantee or other cost performance measure in a clear and consistent manner; and]
(h)(1)(B)(iii)(iii) [inserted: ]
[inserted: where a pricing guarantee or other cost performance measure is based on a pricing benchmark other than the wholesale acquisition cost (as defined in section 1847A(c)(6)(B)) of a drug, calculate and provide a wholesale acquisition cost-based equivalent to the pricing guarantee or other cost performance measure.]
(h)(1)(C)(C) [inserted: Provision of information.—]
(h)(1)(C)(i)(i) [inserted: In general.—]
[inserted: Not later than July 1 of each year, beginning in 2029, the pharmacy benefit manager shall submit to the PDP sponsor, and to the Secretary, a report, in accordance with this subparagraph, and shall make such report available to such sponsor at no cost to such sponsor in a format specified by the Secretary under paragraph (5). Each such report shall include, with respect to such PDP sponsor and each plan offered by such sponsor, the following information with respect to the previous plan year:]
(h)(1)(C)(i)(I)(I) [inserted: ]
[inserted: A list of all drugs covered by the plan that were dispensed including, with respect to each such drug—]
(h)(1)(C)(i)(I)(aa)(aa) [inserted: ]
[inserted: the brand name, generic or non-proprietary name, and National Drug Code;]
(h)(1)(C)(i)(I)(bb)(bb) [inserted: ]
[inserted: the number of plan enrollees for whom the drug was dispensed, the total number of prescription claims for the drug (including original prescriptions and refills, counted as separate claims), and the total number of dosage units of the drug dispensed;]
(h)(1)(C)(i)(I)(cc)(cc) [inserted: ]
[inserted: the number of prescription claims described in item (bb) by each type of dispensing channel through which the drug was dispensed, including retail, mail order, specialty pharmacy, long term care pharmacy, home infusion pharmacy, or other types of pharmacies or providers;]
(h)(1)(C)(i)(I)(dd)(dd) [inserted: ]
[inserted: the average wholesale acquisition cost, listed as cost per day’s supply, cost per dosage unit, and cost per typical course of treatment (as applicable);]
(h)(1)(C)(i)(I)(ee)(ee) [inserted: ]
[inserted: the average wholesale price for the drug, listed as price per day’s supply, price per dosage unit, and price per typical course of treatment (as applicable);]
(h)(1)(C)(i)(I)(ff)(ff) [inserted: ]
[inserted: the total out-of-pocket spending by plan enrollees on such drug after application of any benefits under the plan, including plan enrollee spending through copayments, coinsurance, and deductibles;]
(h)(1)(C)(i)(I)(gg)(gg) [inserted: ]
[inserted: total rebates paid by the manufacturer on the drug as reported under the Detailed DIR Report (or any successor report) submitted by such sponsor to the Centers for Medicare & Medicaid Services;]
(h)(1)(C)(i)(I)(hh)(hh) [inserted: ]
[inserted: all other direct or indirect remuneration on the drug as reported under the Detailed DIR Report (or any successor report) submitted by such sponsor to the Centers for Medicare & Medicaid Services;]
(h)(1)(C)(i)(I)(ii)(ii) [inserted: ]
[inserted: the average pharmacy reimbursement amount paid by the plan for the drug in the aggregate and disaggregated by dispensing channel identified in item (cc);]
(h)(1)(C)(i)(I)(jj)(jj) [inserted: ]
[inserted: the average National Average Drug Acquisition Cost (NADAC); and]
(h)(1)(C)(i)(I)(kk)(kk) [inserted: ]
[inserted: total manufacturer-derived revenue, inclusive of bona fide service fees, attributable to the drug and retained by the pharmacy benefit manager and any affiliate of such pharmacy benefit manager.]
(h)(1)(C)(i)(II)(II) [inserted: ]
[inserted: In the case of a pharmacy benefit manager that has an affiliate that is a retail, mail order, or specialty pharmacy, with respect to drugs covered by such plan that were dispensed, the following information:]
(h)(1)(C)(i)(II)(aa)(aa) [inserted: ]
[inserted: The percentage of total prescriptions that were dispensed by pharmacies that are an affiliate of the pharmacy benefit manager for each drug.]
(h)(1)(C)(i)(II)(bb)(bb) [inserted: ]
[inserted: The interquartile range of the total combined costs paid by the plan and plan enrollees, per dosage unit, per course of treatment, per 30-day supply, and per 90-day supply for each drug dispensed by pharmacies that are not an affiliate of the pharmacy benefit manager and that are included in the pharmacy network of such plan.]
(h)(1)(C)(i)(II)(cc)(cc) [inserted: ]
[inserted: The interquartile range of the total combined costs paid by the plan and plan enrollees, per dosage unit, per course of treatment, per 30-day supply, and per 90-day supply for each drug dispensed by pharmacies that are an affiliate of the pharmacy benefit manager and that are included in the pharmacy network of such plan.]
(h)(1)(C)(i)(II)(dd)(dd) [inserted: ]
[inserted: The lowest total combined cost paid by the plan and plan enrollees, per dosage unit, per course of treatment, per 30-day supply, and per 90-day supply, for each drug that is available from any pharmacy included in the pharmacy network of such plan.]
(h)(1)(C)(i)(II)(ee)(ee) [inserted: ]
[inserted: The difference between the average acquisition cost of the affiliate, such as a pharmacy or other entity that acquires prescription drugs, that initially acquires the drug and the amount reported under subclause (I)(jj) for each drug.]
(h)(1)(C)(i)(II)(ff)(ff) [inserted: ]
[inserted: A list inclusive of the brand name, generic or non-proprietary name, and National Drug Code of covered part D drugs subject to an agreement with a covered entity under section 340B of the Public Health Service Act for which the pharmacy benefit manager or an affiliate of the pharmacy benefit manager had a contract or other arrangement with such a covered entity in the service area of such plan.]
(h)(1)(C)(i)(III)(III) [inserted: ]
[inserted: Where a drug approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act (referred to in this subclause as the “listed drug”) is covered by the plan, the following information:]
(h)(1)(C)(i)(III)(aa)(aa) [inserted: ]
[inserted: A list of currently marketed generic drugs approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act pursuant to an application that references such listed drug that are not covered by the plan, are covered on the same formulary tier or a formulary tier typically associated with higher cost-sharing than the listed drug, or are subject to utilization management that the listed drug is not subject to.]
(h)(1)(C)(i)(III)(bb)(bb) [inserted: ]
[inserted: The estimated average beneficiary cost-sharing under the plan for a 30-day supply of the listed drug.]
(h)(1)(C)(i)(III)(cc)(cc) [inserted: ]
[inserted: Where a generic drug listed under item (aa) is on a formulary tier typically associated with higher cost-sharing than the listed drug, the estimated average cost-sharing that a beneficiary would have paid for a 30-day supply of each of the generic drugs described in item (aa), had the plan provided coverage for such drugs on the same formulary tier as the listed drug.]
(h)(1)(C)(i)(III)(dd)(dd) [inserted: ]
[inserted: A written justification for providing more favorable coverage of the listed drug than the generic drugs described in item (aa).]
(h)(1)(C)(i)(III)(ee)(ee) [inserted: ]
[inserted: The number of currently marketed generic drugs approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act pursuant to an application that references such listed drug.]
(h)(1)(C)(i)(IV)(IV) [inserted: ]
[inserted: Where a reference product (as defined in section 351(i) of the Public Health Service Act) is covered by the plan, the following information:]
(h)(1)(C)(i)(IV)(aa)(aa) [inserted: ]
[inserted: A list of currently marketed biosimilar biological products licensed under section 351(k) of the Public Health Service Act pursuant to an application that refers to such reference product that are not covered by the plan, are covered on the same formulary tier or a formulary tier typically associated with higher cost-sharing than the reference product, or are subject to utilization management that the reference product is not subject to.]
(h)(1)(C)(i)(IV)(bb)(bb) [inserted: ]
[inserted: The estimated average beneficiary cost-sharing under the plan for a 30-day supply of the reference product.]
(h)(1)(C)(i)(IV)(cc)(cc) [inserted: ]
[inserted: Where a biosimilar biological product listed under item (aa) is on a formulary tier typically associated with higher cost-sharing than the reference product, the estimated average cost-sharing that a beneficiary would have paid for a 30-day supply of each of the biosimilar biological products described in item (aa), had the plan provided coverage for such products on the same formulary tier as the reference product.]
(h)(1)(C)(i)(IV)(dd)(dd) [inserted: ]
[inserted: A written justification for providing more favorable coverage of the reference product than the biosimilar biological product described in item (aa).]
(h)(1)(C)(i)(IV)(ee)(ee) [inserted: ]
[inserted: The number of currently marketed biosimilar biological products licensed under section 351(k) of the Public Health Service Act, pursuant to an application that refers to such reference product.]
(h)(1)(C)(i)(V)(V) [inserted: ]
[inserted: Total gross spending on covered part D drugs by the plan, not net of rebates, fees, discounts, or other direct or indirect remuneration.]
(h)(1)(C)(i)(VI)(VI) [inserted: ]
[inserted: The total amount retained by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager in revenue related to utilization of covered part D drugs under that plan, inclusive of bona fide service fees.]
(h)(1)(C)(i)(VII)(VII) [inserted: ]
[inserted: The total spending on covered part D drugs net of rebates, fees, discounts, or other direct and indirect remuneration by the plan.]
(h)(1)(C)(i)(VIII)(VIII) [inserted: ]
[inserted: An explanation of any benefit design parameters under such plan that encourage plan enrollees to fill prescriptions at pharmacies that are an affiliate of such pharmacy benefit manager, such as mail and specialty home delivery programs, and retail and mail auto-refill programs.]
(h)(1)(C)(i)(IX)(IX) [inserted: ]
[inserted: The following information:]
(h)(1)(C)(i)(IX)(aa)(aa) [inserted: ]
[inserted: A list of all brokers, consultants, advisors, and auditors that receive compensation from the pharmacy benefit manager or an affiliate of such pharmacy benefit manager for referrals, consulting, auditing, or other services offered to PDP sponsors related to pharmacy benefit management services.]
(h)(1)(C)(i)(IX)(bb)(bb) [inserted: ]
[inserted: The amount of compensation provided by such pharmacy benefit manager or affiliate to each such broker, consultant, advisor, and auditor.]
(h)(1)(C)(i)(IX)(cc)(cc) [inserted: ]
[inserted: The methodology for calculating the amount of compensation provided by such pharmacy benefit manager or affiliate, for each such broker, consultant, advisor, and auditor.]
(h)(1)(C)(i)(X)(X) [inserted: ]
[inserted: A list of all affiliates of the pharmacy benefit manager.]
(h)(1)(C)(i)(XI)(XI) [inserted: ]
[inserted: A summary document submitted in a standardized template developed by the Secretary that includes such information described in subclauses (I) through (X).]
(h)(1)(C)(ii)(ii) [inserted: Written explanation of contracts or agreements with drug manufacturers.—]
(h)(1)(C)(ii)(I)(I) [inserted: In general.—]
[inserted: The pharmacy benefit manager shall, not later than 30 days after the finalization of any contract or agreement between such pharmacy benefit manager or an affiliate of such pharmacy benefit manager and a drug manufacturer (or subsidiary, agent, or entity affiliated with such drug manufacturer) that makes rebates, discounts, payments, or other financial incentives related to one or more covered part D drugs or other prescription drugs, as applicable, of the manufacturer directly or indirectly contingent upon coverage, formulary placement, or utilization management conditions on any other covered part D drugs or other prescription drugs, as applicable, submit to the PDP sponsor a written explanation of such contract or agreement.]
(h)(1)(C)(ii)(II)(II) [inserted: Requirements.—]
[inserted: A written explanation under subclause (I) shall—]
(h)(1)(C)(ii)(II)(aa)(aa) [inserted: ]
[inserted: include the manufacturer subject to the contract or agreement, all covered part D drugs and other prescription drugs, as applicable, subject to the contract or agreement and the manufacturers of such drugs, and a high-level description of the terms of such contract or agreement and how such terms apply to such drugs; and]
(h)(1)(C)(ii)(II)(bb)(bb) [inserted: ]
[inserted: be certified by the Chief Executive Officer, Chief Financial Officer, or General Counsel of such pharmacy benefit manager, or affiliate of such pharmacy benefit manager, as applicable, or an individual delegated with the authority to sign on behalf of one of these officers, who reports directly to the officer.]
(h)(1)(C)(ii)(III)(III) [inserted: Definition of other prescription drugs.—]
[inserted: For purposes of this clause, the term “other prescription drugs” means prescription drugs covered as supplemental benefits under this part or prescription drugs paid outside of this part.]
(h)(1)(D)(D) [inserted: Audit rights.—]
(h)(1)(D)(i)(i) [inserted: In general.—]
[inserted: Not less than once a year, at the request of the PDP sponsor, the pharmacy benefit manager shall allow for an audit of the pharmacy benefit manager to ensure compliance with all terms and conditions under the written agreement described in this paragraph and the accuracy of information reported under subparagraph (C).]
(h)(1)(D)(ii)(ii) [inserted: Auditor.—]
[inserted: The PDP sponsor shall have the right to select an auditor. The pharmacy benefit manager shall not impose any limitations on the selection of such auditor.]
(h)(1)(D)(iii)(iii) [inserted: Provision of information.—]
[inserted: The pharmacy benefit manager shall make available to such auditor all records, data, contracts, and other information necessary to confirm the accuracy of information provided under subparagraph (C), subject to reasonable restrictions on how such information must be reported to prevent redisclosure of such information.]
(h)(1)(D)(iv)(iv) [inserted: Timing.—]
[inserted: The pharmacy benefit manager must provide information under clause (iii) and other information, data, and records relevant to the audit to such auditor within 6 months of the initiation of the audit and respond to requests for additional information from such auditor within 30 days after the request for additional information.]
(h)(1)(D)(v)(v) [inserted: Information from affiliates.—]
[inserted: The pharmacy benefit manager shall be responsible for providing to such auditor information required to be reported under subparagraph (C) or under clause (iii) of this subparagraph that is owned or held by an affiliate of such pharmacy benefit manager.]
(h)(2)(2) [inserted: Enforcement.—]
(h)(2)(A)(A) [inserted: In general.—]
[inserted: Each PDP sponsor shall—]
(h)(2)(A)(i)(i) [inserted: ]
[inserted: disgorge to the Secretary any amounts disgorged to the PDP sponsor by a pharmacy benefit manager under paragraph (1)(A)(v);]
(h)(2)(A)(ii)(ii) [inserted: ]
[inserted: require, in a written agreement with any pharmacy benefit manager acting on behalf of such sponsor or affiliate of such pharmacy benefit manager, that such pharmacy benefit manager or affiliate reimburse the PDP sponsor for any civil money penalty imposed on the PDP sponsor as a result of the failure of the pharmacy benefit manager or affiliate to meet the requirements of paragraph (1) that are applicable to the pharmacy benefit manager or affiliate under the agreement; and]
(h)(2)(A)(iii)(iii) [inserted: ]
[inserted: require, in a written agreement with any such pharmacy benefit manager acting on behalf of such sponsor or affiliate of such pharmacy benefit manager, that such pharmacy benefit manager or affiliate be subject to punitive remedies for breach of contract for failure to comply with the requirements applicable under paragraph (1).]
(h)(2)(B)(B) [inserted: Reporting of alleged violations.—]
[inserted: The Secretary shall make available and maintain a mechanism for manufacturers, PDP sponsors, pharmacies, and other entities that have contractual relationships with pharmacy benefit managers or affiliates of such pharmacy benefit managers to report, on a confidential basis, alleged violations of paragraph (1)(A) or subparagraph (C).]
(h)(2)(C)(C) [inserted: Anti-retaliation and anti-coercion.—]
[inserted: Consistent with applicable Federal or State law, a PDP sponsor shall not—]
(h)(2)(C)(i)(i) [inserted: ]
[inserted: retaliate against an individual or entity for reporting an alleged violation under subparagraph (B); or]
(h)(2)(C)(ii)(ii) [inserted: ]
[inserted: coerce, intimidate, threaten, or interfere with the ability of an individual or entity to report any such alleged violations.]
(h)(3)(3) [inserted: Certification of compliance.—]
(h)(3)(A)(A) [inserted: In general.—]
[inserted: Each PDP sponsor shall furnish to the Secretary (at a time and in a manner specified by the Secretary) an annual certification of compliance with this subsection, as well as such information as the Secretary determines necessary to carry out this subsection.]
(h)(3)(B)(B) [inserted: Implementation.—]
[inserted: Notwithstanding any other provision of law, the Secretary may implement this paragraph by program instruction or otherwise.]
(h)(4)(4) [inserted: Rule of construction.—]
[inserted: Nothing in this subsection shall be construed as—]
(h)(4)(A)(A) [inserted: ]
[inserted: prohibiting flat dispensing fees or reimbursement or payment for ingredient costs (including customary, industry-standard discounts directly related to drug acquisition that are retained by pharmacies or wholesalers) to entities that acquire or dispense prescription drugs; or]
(h)(4)(B)(B) [inserted: ]
[inserted: modifying regulatory requirements or sub-regulatory program instruction or guidance related to pharmacy payment, reimbursement, or dispensing fees.]
(h)(5)(5) [inserted: Standard formats.—]
(h)(5)(A)(A) [inserted: In general.—]
[inserted: Not later than June 1, 2028, the Secretary shall specify standard, machine-readable formats for pharmacy benefit managers to submit annual reports required under paragraph (1)(C)(i).]
(h)(5)(B)(B) [inserted: Implementation.—]
[inserted: Notwithstanding any other provision of law, the Secretary may implement this paragraph by program instruction or otherwise.]
(h)(6)(6) [inserted: Confidentiality.—]
(h)(6)(A)(A) [inserted: In general.—]
[inserted: Information disclosed by a pharmacy benefit manager, an affiliate of a pharmacy benefit manager, a PDP sponsor, or a pharmacy under this subsection that is not otherwise publicly available or available for purchase shall not be disclosed by the Secretary or a PDP sponsor receiving the information, except that the Secretary may disclose the information for the following purposes:]
(h)(6)(A)(i)(i) [inserted: ]
[inserted: As the Secretary determines necessary to carry out this part.]
(h)(6)(A)(ii)(ii) [inserted: ]
[inserted: To permit the Comptroller General to review the information provided.]
(h)(6)(A)(iii)(iii) [inserted: ]
[inserted: To permit the Director of the Congressional Budget Office to review the information provided.]
(h)(6)(A)(iv)(iv) [inserted: ]
[inserted: To permit the Executive Director of the Medicare Payment Advisory Commission to review the information provided.]
(h)(6)(A)(v)(v) [inserted: ]
[inserted: To the Attorney General for the purposes of conducting oversight and enforcement under this title.]
(h)(6)(A)(vi)(vi) [inserted: ]
[inserted: To the Inspector General of the Department of Health and Human Services in accordance with its authorities under the Inspector General Act of 1978 (section 406 of title 5, United States Code), and other applicable statutes.]
(h)(6)(B)(B) [inserted: Restriction on use of information.—]
[inserted: The Secretary, the Comptroller General, the Director of the Congressional Budget Office, and the Executive Director of the Medicare Payment Advisory Commission shall not report on or disclose information disclosed pursuant to subparagraph (A) to the public in a manner that would identify—]
(h)(6)(B)(i)(i) [inserted: ]
[inserted: a specific pharmacy benefit manager, affiliate, pharmacy, manufacturer, wholesaler, PDP sponsor, or plan; or]
(h)(6)(B)(ii)(ii) [inserted: ]
[inserted: contract prices, rebates, discounts, or other remuneration for specific drugs in a manner that may allow the identification of specific contracting parties or of such specific drugs.]
(h)(7)(7) [inserted: Definitions.—]
[inserted: For purposes of this subsection:]
(h)(7)(A)(A) [inserted: Affiliate.—]
[inserted: The term “affiliate” means, with respect to any pharmacy benefit manager or PDP sponsor, any entity that, directly or indirectly—]
(h)(7)(A)(i)(i) [inserted: ]
[inserted: owns or is owned by, controls or is controlled by, or is otherwise related in any ownership structure to such pharmacy benefit manager or PDP sponsor; or]
(h)(7)(A)(ii)(ii) [inserted: ]
[inserted: acts as a contractor, principal, or agent to such pharmacy benefit manager or PDP sponsor, insofar as such contractor, principal, or agent performs any of the functions described under subparagraph (C).]
(h)(7)(B)(B) [inserted: Bona fide service fee.—]
[inserted: The term “bona fide service fee” means a fee that is reflective of the fair market value (as specified by the Secretary, through notice and comment rulemaking) for a bona fide, itemized service actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug. Such fee must be a flat dollar amount and shall not be directly or indirectly based on, or contingent upon—]
(h)(7)(B)(i)(i) [inserted: ]
[inserted: drug price, such as wholesale acquisition cost or drug benchmark price (such as average wholesale price);]
(h)(7)(B)(ii)(ii) [inserted: ]
[inserted: the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to covered part D drugs dispensed to enrollees in a prescription drug plan, except as permitted pursuant to paragraph (1)(A)(ii);]
(h)(7)(B)(iii)(iii) [inserted: ]
[inserted: coverage or formulary placement decisions or the volume or value of any referrals or business generated between the parties to the arrangement; or]
(h)(7)(B)(iv)(iv) [inserted: ]
[inserted: any other amounts or methodologies prohibited by the Secretary.]
(h)(7)(C)(C) [inserted: Pharmacy benefit manager.—]
[inserted: The term “pharmacy benefit manager” means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a PDP sponsor or prescription drug plan, or manages the prescription drug benefits provided by such sponsor or plan, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered part D drugs, or the provision of related services. Such term includes any person or entity that carries out one or more of the activities described in the preceding sentence, irrespective of whether such person or entity calls itself a “pharmacy benefit manager”.]

42 U.S.C. § 18031 Affordable choices of health benefit plans

+32 −2Shown
More for 42 U.S.C. § 18031
Read § 18031Only this section
5 changes the bill asks for here, 5 carried out
  1. Carried out:

    Section 1311(c) of the Patient Protection and Affordable Care Act (42 U.S.C. 18031(c)) is amended by adding at the end the following new paragraph:(8) Agent- or broker-assisted enrollment in qualified health plans in certain exchanges.— (A) In general.— For plan years beginning on or after such date specified by the Secretary, but not later than January 1, 2029, in the case of an Exchange that the Secretary operates …

  2. Carried out:

    in subparagraph (H), by striking and at the end;

  3. Carried out:

    in subparagraph (I), by striking the period at the end and inserting ; and; and

  4. Carried out:

    by adding at the end the following:(J) report to the Secretary the termination (as defined in section 1312(e)(1)(C)) of an issuer..

  5. Carried out:

    Section 1311(c) of the Patient Protection and Affordable Care Act (42 U.S.C. 18031(c)), as amended by subsection (a), is further amended by adding at the end the following new paragraph:(9) Removal of deceased individuals from Exchange plans.— (A) In general.— Not later than 90 days after the date of the enactment of this paragraph, and on a quarterly basis thereafter, the Secretary shall conduct a check of the Death Master File (as such term is defined in …

§ 18031(c)Responsibilities of the Secretary(1)–(3)

Start of § 18031 to (c)(1)(F) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(G)(G) (G)
utilize the standard format established for presenting health benefits plan options;utilize the standard format established for presenting health benefits plan options;
(1)(H)(H) (H)
provide information to enrollees and prospective enrollees, and to each Exchange in which the plan is offered, on any quality measures for health plan performance endorsed under section 399JJ of the Public Health Service Act [42 U.S.C. 280j–2], as applicable;[struck: and]provide information to enrollees and prospective enrollees, and to each Exchange in which the plan is offered, on any quality measures for health plan performance endorsed under section 399JJ of the Public Health Service Act [42 U.S.C. 280j–2], as applicable;
(1)(I)(I) (I)
report to the Secretary at least annually and in such manner as the Secretary shall require, pediatric quality reporting measures consistent with the pediatric quality reporting measures established under section 1139A of the Social Security Act [42 U.S.C. 1320b–9a][struck: .]report to the Secretary at least annually and in such manner as the Secretary shall require, pediatric quality reporting measures consistent with the pediatric quality reporting measures established under section 1139A of the Social Security Act [42 U.S.C. 1320b–9a][inserted: ; and]
(1)(J)(J) [inserted: ]
[inserted: report to the Secretary the termination (as defined in section 1312(e)(1)(C)) of an issuer.]
(2)(2) Rule of construction(2) Rule of construction
Nothing in paragraph (1)(C) shall be construed to require a qualified health plan to contract with a provider described in such paragraph if such provider refuses to accept the generally applicable payment rates of such plan.Nothing in paragraph (1)(C) shall be construed to require a qualified health plan to contract with a provider described in such paragraph if such provider refuses to accept the generally applicable payment rates of such plan.
(3)(3) Rating system(3) Rating system
The Secretary shall develop a rating system that would rate qualified health plans offered through an Exchange in each benefits level on the basis of the relative quality and price. The Exchange shall include the quality rating in the information provided to individuals and employers through the Internet portal established under paragraph (4).The Secretary shall develop a rating system that would rate qualified health plans offered through an Exchange in each benefits level on the basis of the relative quality and price. The Exchange shall include the quality rating in the information provided to individuals and employers through the Internet portal established under paragraph (4).

§ 18031(c)–(d)

(c)(4)–(7) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(7)(B)(ii)(ii) (ii)
is enrolled in a qualified health plan during such plan year and does not enroll in a qualified health plan for plan year 2021 during the annual open enrollment period for such plan year 2021; andis enrolled in a qualified health plan during such plan year and does not enroll in a qualified health plan for plan year 2021 during the annual open enrollment period for such plan year 2021; and
(c)(7)(B)(iii)(iii) (iii)
does not elect to disenroll under a qualified health plan for plan year 2021 during such annual open enrollment period.does not elect to disenroll under a qualified health plan for plan year 2021 during such annual open enrollment period.
(c)(8)(8) [inserted: Agent- or broker-assisted enrollment in qualified health plans in certain exchanges.—]
(c)(8)(A)(A) [inserted: In general.—]
[inserted: For plan years beginning on or after such date specified by the Secretary, but not later than January 1, 2029, in the case of an Exchange that the Secretary operates pursuant to section 1321(c)(1), the Secretary shall establish a verification process for new enrollments of individuals in, and changes in coverage for individuals under, a qualified health plan offered through such Exchange, which are submitted by an agent or broker in accordance with section 1312(e) and for which the agent or broker is eligible to receive a commission.]
(c)(8)(B)(B) [inserted: Requirements.—]
[inserted: The enrollment verification process under subparagraph (A) shall include—]
(c)(8)(B)(i)(i) [inserted: ]
[inserted: a requirement that the agent or broker provide with the new enrollment or coverage change such documentation or evidence (such as a standardized consent form) or other sources as the Secretary determines necessary to establish that the agent or broker has the consent of the individual for the new enrollment or coverage change;]
(c)(8)(B)(ii)(ii) [inserted: ]
[inserted: a requirement that any commissions due to a broker or agent for such new enrollment or coverage change are paid after the enrollee has resolved all inconsistencies in accordance with paragraphs (3) and (4) of section 1411(e);]
(c)(8)(B)(iii)(iii) [inserted: ]
[inserted: a requirement that the information required under clause (i) and, as applicable, the date on which inconsistencies are resolved as described in clause (ii), is accessible to the applicable qualified health plan through a database or other resource, as determined by the Secretary, so that any commissions due to a broker or agent for such enrollment can be effectuated at the appropriate time;]
(c)(8)(B)(iv)(iv) [inserted: ]
[inserted: a requirement that individuals are notified of any changes to enrollment, coverage, the agent of record, or premium tax credits in a timely manner and that such notice provides plain language instructions on how individuals can cancel unauthorized activity;]
(c)(8)(B)(v)(v) [inserted: ]
[inserted: a requirement that individuals be able to access their account information on a website or other technology platform, as defined by the Secretary, when used to submit an enrollment or plan change, in lieu of the Exchange website described in subsection (d)(4)(C), including information on the agent of record, the qualified health plan, and when any changes are made to the agent of record or the qualified health plan, on a consumer-facing website or through a toll-free telephone hotline; and]
(c)(8)(B)(vi)(vi) [inserted: ]
[inserted: a requirement that the agent or broker report to the Secretary any third-party marketing organization or field marketing organization (as such terms are defined in section 1312(e)) involved in the chain of enrollment (as so defined) with respect to such new enrollment or coverage change.]
(c)(8)(C)(C) [inserted: Consumer protection.—]
[inserted: The Secretary shall ensure that the enrollment verification process under subparagraph (A) prioritizes continuity of coverage and care for individuals, including by not disenrolling individuals from a qualified health plan without the consent of the individual, regardless of whether the broker, agent, or qualified health plan is in violation of any requirement under this paragraph.]
(c)(9)(9) [inserted: Removal of deceased individuals from Exchange plans.—]
(c)(9)(A)(A) [inserted: In general.—]
[inserted: Not later than 90 days after the date of the enactment of this paragraph, and on a quarterly basis thereafter, the Secretary shall conduct a check of the Death Master File (as such term is defined in section 203(d) of the Bipartisan Budget Act of 2013) for purposes of identifying individuals enrolled in a qualified health plan through an Exchange who are deceased.]
(c)(9)(B)(B) [inserted: Process.—]
[inserted: The Secretary shall—]
(c)(9)(B)(i)(i) [inserted: ]
[inserted: establish a process to verify that an individual identified pursuant to a check described in subparagraph (A) is deceased; and]
(c)(9)(B)(ii)(ii) [inserted: ]
[inserted: require an Exchange to terminate such individual’s enrollment under a qualified health plan.]
(d)(d) Requirements(d) Requirements
(d)(1)(1) In general(1) In general
An Exchange shall be a governmental agency or nonprofit entity that is established by a State.An Exchange shall be a governmental agency or nonprofit entity that is established by a State.

Rest of § 18031 unchanged

42 U.S.C. § 18032 Consumer choice

+75 −45 of 6 shown
More for 42 U.S.C. § 18032
Read § 18032Only this section
6 changes the bill asks for here, 5 carried out
  1. Carried out:

    by redesignating paragraphs (1) and (2) as subclauses (I) and (II), respectively, and adjusting the margins accordingly;

  2. Carried out:

    in subclause (II) (as so redesignated), by striking the period at the end and inserting ; and;

  3. Not carried out:

    by striking the subsection designation and heading and all that follows through brokers— and inserting the following:(e) Regulation of agents, brokers, and certain marketing organizations.— (1) Agents, brokers, and certain marketing organizations.— (A) In general.— The Secretary shall establish procedures under which a State may allow— (i) agents or brokers—; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking the subsection designation and heading and all that follows through QTEXT and inserting the following: QCONTENT; and
  4. Carried out:

    by adding at the end the following:(ii) field marketing organizations and third-party marketing organizations to participate in the chain of enrollment for an individual with respect to qualified health plans offered through an Exchange. (B) Criteria.— For plan years beginning on or after such date specified by …

  5. Carried out:

    Section 1312(e) of the Patient Protection and Affordable Care Act (42 U.S.C. 18032(e)), as amended by paragraph (3), is further amended by adding at the end the following new paragraphs:(2) Audits.— (A) In general.— For plan years beginning on or after such date specified by the Secretary, but not later than January 1, 2029, the Secretary, in coordination with the States and in consultation with the National Association of Insurance Commissioners, shall …

  6. Carried out:

    Section 1312(e) of the Patient Protection and Affordable Care Act (42 U.S.C. 18032(e)), as amended by subsection (a), is further amended by adding at the end the following new paragraph:(4) Standard for termination for certain Exchanges.— In the case of an agent or broker with an agreement in effect with an Exchange operated by the Secretary pursuant to section 1321(c) to perform activities described in paragraph (1)(A)(i) with respect to such Exchange, the …

§ 18032(d)–(f)

Start of § 18032 to (d)(3)(D)(ii)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(d)(4)(4) No penalty for transferring to minimum essential coverage outside Exchange(4) No penalty for transferring to minimum essential coverage outside Exchange
An Exchange, or a qualified health plan offered through an Exchange, shall not impose any penalty or other fee on an individual who cancels enrollment in a plan because the individual becomes eligible for minimum essential coverage (as defined in section 5000A(f) of title 26 without regard to paragraph (1)(C) or (D) thereof) or such coverage becomes affordable (within the meaning of section 36B(c)(2)(C) of such title).An Exchange, or a qualified health plan offered through an Exchange, shall not impose any penalty or other fee on an individual who cancels enrollment in a plan because the individual becomes eligible for minimum essential coverage (as defined in section 5000A(f) of title 26 without regard to paragraph (1)(C) or (D) thereof) or such coverage becomes affordable (within the meaning of section 36B(c)(2)(C) of such title).
(e)(e) Enrollment through agents or brokers(e) Enrollment through agents or brokers
The Secretary shall establish procedures under which a State may allow agents or brokers—The Secretary shall establish procedures under which a State may allow agents or brokers—
(e)(I)[struck: (1)] [inserted: (I)]
to enroll individuals and employers in any qualified health plans in the individual or small group market as soon as the plan is offered through an Exchange in the State; andto enroll individuals and employers in any qualified health plans in the individual or small group market as soon as the plan is offered through an Exchange in the State; and
(e)(II)[struck: (2)] [inserted: (II)]
to assist individuals in applying for premium tax credits and cost-sharing reductions for plans sold through an Exchange[struck: .]to assist individuals in applying for premium tax credits and cost-sharing reductions for plans sold through an Exchange[inserted: ; and]
(e)(ii)(ii) [inserted: ]
[inserted: field marketing organizations and third-party marketing organizations to participate in the chain of enrollment for an individual with respect to qualified health plans offered through an Exchange.]
(e)(B)(B) [inserted: Criteria.—]
[inserted: For plan years beginning on or after such date specified by the Secretary, but not later than January 1, 2029, the Secretary, by regulation, shall establish criteria for States to use in determining whether to allow agents and brokers to enroll individuals and employers in qualified health plans as described in subclause (I) of subparagraph (A)(i) and to assist individuals as described in subclause (II) of such subparagraph and field marketing organizations and third-party marketing organizations to participate in the chain of enrollment as described in subparagraph (A)(ii). Such criteria shall, at a minimum, require that—]
(e)(B)(i)(i) [inserted: ]
[inserted: an agent or broker act in accordance with a standard of conduct that includes a duty of such agent or broker to act in the best interests of the enrollee;]
(e)(B)(ii)(ii) [inserted: ]
[inserted: a field marketing organization or third-party marketing organization agree to report the termination of an agent or broker to the applicable State and the Secretary, including the reason for termination; and]
(e)(B)(iii)(iii) [inserted: ]
[inserted: an agent, broker, field marketing organization, or third-party marketing organization—]
(e)(B)(iii)(I)(I) [inserted: ]
[inserted: meet such marketing requirements as are required by the Secretary;]
(e)(B)(iii)(II)(II) [inserted: ]
[inserted: meet marketing requirements in accordance with other applicable Federal or State law;]
(e)(B)(iii)(III)(III) [inserted: ]
[inserted: does not employ practices that are confusing or misleading, as determined by the Secretary;]
(e)(B)(iii)(IV)(IV) [inserted: ]
[inserted: submit all marketing materials to the Secretary for, as determined appropriate by the Secretary, review and approval;]
(e)(B)(iii)(V)(V) [inserted: ]
[inserted: is a licensed agent or broker or meets other licensure requirements, as required by the State;]
(e)(B)(iii)(VI)(VI) [inserted: ]
[inserted: register with the Secretary; and]
(e)(B)(iii)(VII)(VII) [inserted: ]
[inserted: does not compensate any individual or organization for referrals or any other service relating to the sale of, marketing for, or enrollment in qualified health plans unless such individual or organization meets the criteria described in subclauses (I) through (VI).]
(e)(C)(C) [inserted: Definitions.—]
[inserted: In this paragraph:]
(e)(C)(i)(i) [inserted: Chain of enrollment.—]
[inserted: The term “chain of enrollment”, with respect to enrollment of an individual in a qualified health plan offered through an Exchange, means any steps taken from marketing to such individual, to such individual making an enrollment decision with respect to such a plan.]
(e)(C)(ii)(ii) [inserted: Field marketing organization.—]
[inserted: The term “field marketing organization” means an organization or individual that directly employs or contracts with agents and brokers, or contracts with carriers, to provide functions relating to enrollment of individuals in qualified health plans offered through an Exchange as part of the chain of enrollment.]
(e)(C)(iii)(iii) [inserted: Marketing.—]
[inserted: The term “marketing” means the use of marketing materials to provide information to current and prospective enrollees in a qualified health plan offered through an Exchange.]
(e)(C)(iv)(iv) [inserted: Marketing materials.—]
[inserted: The term “marketing materials” means materials relating to a qualified health plan offered through an Exchange or benefits offered through an Exchange that—]
(e)(C)(iv)(I)(I) [inserted: ]
[inserted: are intended—]
(e)(C)(iv)(I)(aa)(aa) [inserted: ]
[inserted: to draw an individual’s attention to such plan or the premium tax credits or cost-sharing reductions for such plan or plans offered through an Exchange;]
(e)(C)(iv)(I)(bb)(bb) [inserted: ]
[inserted: to influence an individual’s decision-making process when selecting a qualified health plan in which to enroll; or]
(e)(C)(iv)(I)(cc)(cc) [inserted: ]
[inserted: to influence an enrollee’s decision to stay enrolled in such plan; and]
(e)(C)(iv)(II)(II) [inserted: ]
[inserted: include or address content regarding the benefits, benefit structure, premiums, or cost sharing of such plan.]
(e)(C)(v)(v) [inserted: Termination.—]
[inserted: The term “termination”, with respect to a contract or business arrangement between an agent or broker and a field marketing organization, third-party marketing organization, or health insurance issuer, means—]
(e)(C)(v)(I)(I) [inserted: ]
[inserted: the ending of such contract or business arrangement, either unilaterally by one of the parties or on mutual agreement; or]
(e)(C)(v)(II)(II) [inserted: ]
[inserted: the expiration of such contract or business arrangement that is not replaced by a substantially similar agreement.]
(e)(C)(vi)(vi) [inserted: Third-party marketing organization.—]
[inserted: The term “third-party marketing organization” means an organization or individual that is compensated to perform lead generation, marketing, or sales relating to enrollment of individuals in qualified health plans offered through an Exchange as part of the chain of enrollment.]
(e)(2)(2) [inserted: Audits.—]
(e)(2)(A)(A) [inserted: In general.—]
[inserted: For plan years beginning on or after such date specified by the Secretary, but not later than January 1, 2029, the Secretary, in coordination with the States and in consultation with the National Association of Insurance Commissioners, shall implement a process for the oversight and enforcement of agent and broker compliance with this section and other applicable Federal and State law (including regulations) that shall include—]
(e)(2)(A)(i)(i) [inserted: ]
[inserted: periodic audits of agents and brokers based on—]
(e)(2)(A)(i)(I)(I) [inserted: ]
[inserted: complaints filed with the Secretary by individuals enrolled by such an agent or broker in a qualified health plan offered through an Exchange;]
(e)(2)(A)(i)(II)(II) [inserted: ]
[inserted: an incident or enrollment pattern that suggests fraud; and]
(e)(2)(A)(i)(III)(III) [inserted: ]
[inserted: other factors determined by the Secretary; and]
(e)(2)(A)(ii)(ii) [inserted: ]
[inserted: a process under which the Secretary shall share audit results and refer potential cases of fraud to the relevant State department of insurance.]
(e)(2)(B)(B) [inserted: Effect.—]
[inserted: Nothing in this paragraph limits or restricts any referrals made under section 1311(i)(3) or any enforcement actions under section 1411(h).]
(e)(3)(3) [inserted: List.—]
[inserted: The Secretary shall develop a process to regularly provide to qualified health plans, Exchanges, and States a list of suspended and terminated agents and brokers.]
(e)(4)(4) [inserted: Standard for termination for certain Exchanges.—]
[inserted: In the case of an agent or broker with an agreement in effect with an Exchange operated by the Secretary pursuant to section 1321(c) to perform activities described in paragraph (1)(A)(i) with respect to such Exchange, the Secretary may terminate such agreement if the Secretary finds, based on a preponderance of the evidence, that such agent or broker has violated such agreement, otherwise applicable law, or any other requirement applicable to such agent or broker.]
(f)(f) Qualified individuals and employers; access limited to citizens and lawful residents(f) Qualified individuals and employers; access limited to citizens and lawful residents
(f)(1)(1) Qualified individuals(1) Qualified individuals
In this title: 1In this title: 1

Rest of § 18032 unchanged

42 U.S.C. § 18081 Procedures for determining eligibility for Exchange participation, premium tax credits and reduced cost-sharing, and individual responsibility exemptions

+13 −37 of 9 shown
More for 42 U.S.C. § 18081
Read § 18081Only this section
9 changes the bill asks for here, 7 carried out
  1. Carried out:

    by redesignating clause (ii) as clause (iv);

  2. Not carried out:

    in the matter preceding subclause (I), by striking If— and all that follows through the such person in the matter following subclause (II) and inserting the following: If any person (other than an agent or broker) fails to provide correct information under subsection (b) and such failure is attributable to negligence or disregard of any rules or regulations of the Secretary, such person; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through the QTEXT in the matter following subclause (X) and inserting the following: QTEXT; and
  3. Not carried out:

    in the second sentence, by striking For purposes and inserting the following:(iii) Definitions of negligence, disregard.— For purposes;

    § 18081(h)(1)(A)(i) already has provisions of its own, so its opening words can't simply become the first of them.

    Technical detail/us/usc/t42/s18081/h/1/A/i has provisions already, so its words can't become the first
  4. Carried out:

    by inserting after clause (i) the following:(ii) Civil penalties for certain violations by agents or brokers.— If any agent or broker fails to provide correct information under subsection (b) or section 1311(c)(8) or other information, as specified by the Secretary, and such failure is attributable to negligence or …

  5. Carried out:

    in clause (iv) (as so redesignated), by inserting or (ii) after clause (i);

  6. Carried out:

    by inserting including subparagraph (C), after law,;

  7. Carried out:

    by striking Any person and inserting the following:(i) In general.— Any person; and

  8. Carried out:

    by adding at the end the following:(ii) Civil penalties for knowing violations by agents or brokers.— (I) In general.— Any agent or broker who knowingly provides false or fraudulent information under subsection (b) or section 1311(c)(8), or other false or fraudulent information as part of an application for …

  9. Carried out:

    by adding at the end the following:(C) Criminal penalties.— Any agent or broker who knowingly and willfully provides false or fraudulent information under subsection (b) or section 1311(c)(8), or other false or fraudulent information as part of an application for enrollment in a qualified health plan offered …

§ 18081(h)Penalties(1)–(3)

Start of § 18081 to (h)(1)(A)(i) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(A)(i)(I)(I) (I)
any person fails to provides3 correct information under subsection (b); andany person fails to provides3 correct information under subsection (b); and
(1)(A)(i)(II)(II) (II)
such failure is attributable to negligence or disregard of any rules or regulations of the Secretary,such failure is attributable to negligence or disregard of any rules or regulations of the Secretary,
(1)(A)(ii)(ii) [inserted: Civil penalties for certain violations by agents or brokers.—]
[inserted: If any agent or broker fails to provide correct information under subsection (b) or section 1311(c)(8) or other information, as specified by the Secretary, and such failure is attributable to negligence or disregard of any rules or regulations of the Secretary, such agent or broker shall be subject, in addition to any other penalties that may be prescribed by law, including subparagraph (C), to a civil penalty of not less than $10,000 and not more than $50,000 with respect to each individual who is the subject of an application for which such incorrect information is provided.]
(1)(A)such person shall be subject, in addition to any other penalties that may be prescribed by law, to a civil penalty of not more than $25,000 with respect to any failures involving an application for a plan year. For purposes of this subparagraph, the terms “negligence” and “disregard” shall have the same meanings as when used in section 6662 of title 26.such person shall be subject, in addition to any other penalties that may be prescribed by law, to a civil penalty of not more than $25,000 with respect to any failures involving an application for a plan year. For purposes of this subparagraph, the terms “negligence” and “disregard” shall have the same meanings as when used in section 6662 of title 26.
(1)(A)(iv)[struck: (ii)] Reasonable cause exception[inserted: (iv)] Reasonable cause exception
No penalty shall be imposed under clause (i) if the Secretary determines that there was a reasonable cause for the failure and that the person acted in good faith.No penalty shall be imposed under clause (i) [inserted: or (ii) ]if the Secretary determines that there was a reasonable cause for the failure and that the person acted in good faith.
(1)(B)(B) Knowing and willful violations(B) Knowing and willful violations
(1)(B)(i)(i) [inserted: In general.—]
[inserted: Any person who knowingly and willfully provides false or fraudulent information under subsection (b) shall be subject, in addition to any other penalties that may be prescribed by law, including subparagraph (C), to a civil penalty of not more than $250,000.]
(1)(B)(ii)(ii) [inserted: Civil penalties for knowing violations by agents or brokers.—]
(1)(B)(ii)(I)(I) [inserted: In general.—]
[inserted: Any agent or broker who knowingly provides false or fraudulent information under subsection (b) or section 1311(c)(8), or other false or fraudulent information as part of an application for enrollment in a qualified health plan offered through an Exchange, as specified by the Secretary, shall be subject, in addition to any other penalties that may be prescribed by law, including subparagraph (C), to a civil penalty of not more than $200,000 with respect to each individual who is the subject of an application for which such false or fraudulent information is provided.]
(1)(B)(ii)(II)(II) [inserted: Procedure.—]
[inserted: The provisions of section 1128A of the Social Security Act (other than subsections (a) and (b) of such section) shall apply to a civil monetary penalty under subclause (I) in the same manner as such provisions apply to a penalty or proceeding under section 1128A of the Social Security Act.]
(1)(C)(C) [inserted: Criminal penalties.—]
[inserted: Any agent or broker who knowingly and willfully provides false or fraudulent information under subsection (b) or section 1311(c)(8), or other false or fraudulent information as part of an application for enrollment in a qualified health plan offered through an Exchange, as specified by the Secretary, shall be fined under title 18, United States Code, imprisoned for not more than 10 years, or both.]
(1)(B)[struck: Any person who knowingly and willfully provides false or fraudulent information under subsection (b) shall be subject, in addition to any other penalties that may be prescribed by law, to a civil penalty of not more than $250,000.]
(2)(2) Improper use or disclosure of information(2) Improper use or disclosure of information
Any person who knowingly and willfully uses or discloses information in violation of subsection (g) shall be subject, in addition to any other penalties that may be prescribed by law, to a civil penalty of not more than $25,000.Any person who knowingly and willfully uses or discloses information in violation of subsection (g) shall be subject, in addition to any other penalties that may be prescribed by law, to a civil penalty of not more than $25,000.
(3)(3) Limitations on liens and levies(3) Limitations on liens and levies
The Secretary (or, if applicable, the Attorney General of the United States) shall not—The Secretary (or, if applicable, the Attorney General of the United States) shall not—

Rest of § 18081 unchanged

42 U.S.C. § 18082 Advance determination and payment of premium tax credits and cost-sharing reductions

+2 −0Shown
More for 42 U.S.C. § 18082
Read § 18082Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1412(c)(2) of the Patient Protection and Affordable Care Act (42 U.S.C. 18082(c)(2)) is amended by adding at the end the following new subparagraph:(C) Exchange responsibilities.— Beginning January 1, 2027, if an Exchange is notified under paragraph (1) of an advance determination under section 1411 with respect to the eligibility of an individual for a premium tax credit under section 36B of the Internal Revenue Code of …

§ 18082(c)–(e)

Start of § 18082 to (c)(2)(B)(iv) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(2)(B)(iv)(I)(I) (I)
notify the Secretary of such nonpayment; andnotify the Secretary of such nonpayment; and
(c)(2)(B)(iv)(II)(II) (II)
allow a 3-month grace period for nonpayment of premiums before discontinuing coverage.allow a 3-month grace period for nonpayment of premiums before discontinuing coverage.
(c)(2)(C)(C) [inserted: Exchange responsibilities.—]
[inserted: Beginning January 1, 2027, if an Exchange is notified under paragraph (1) of an advance determination under section 1411 with respect to the eligibility of an individual for a premium tax credit under section 36B of the Internal Revenue Code of 1986, the Exchange shall, prior to enrolling such individual in a qualified health plan, clearly notify such individual of the amount of such tax credit.]
(c)(3)(3) Cost-sharing reductions(3) Cost-sharing reductions
The Secretary shall also notify the Secretary of the Treasury and the Exchange under paragraph (1) if an advance payment of the cost-sharing reductions under section 18071 of this title is to be made to the issuer of any qualified health plan with respect to any individual enrolled in the plan. The Secretary of the Treasury shall make such advance payment at such time and in such amount as the Secretary specifies in the notice.The Secretary shall also notify the Secretary of the Treasury and the Exchange under paragraph (1) if an advance payment of the cost-sharing reductions under section 18071 of this title is to be made to the issuer of any qualified health plan with respect to any individual enrolled in the plan. The Secretary of the Treasury shall make such advance payment at such time and in such amount as the Secretary specifies in the notice.
(d)(d) No Federal payments for individuals not lawfully present(d) No Federal payments for individuals not lawfully present
Nothing in this subtitle or the amendments made by this subtitle allows Federal payments, credits, or cost-sharing reductions for individuals who are not lawfully present in the United States.Nothing in this subtitle or the amendments made by this subtitle allows Federal payments, credits, or cost-sharing reductions for individuals who are not lawfully present in the United States.
(e)(e) State flexibility(e) State flexibility
Nothing in this subtitle or the amendments made by this subtitle shall be construed to prohibit a State from making payments to or on behalf of an individual for coverage under a qualified health plan offered through an Exchange that are in addition to any credits or cost-sharing reductions allowable to the individual under this subtitle and such amendments.Nothing in this subtitle or the amendments made by this subtitle shall be construed to prohibit a State from making payments to or on behalf of an individual for coverage under a qualified health plan offered through an Exchange that are in addition to any credits or cost-sharing reductions allowable to the individual under this subtitle and such amendments.

Step through the changes